Genmab A (GMAB) Receivables - Other (2019 - 2026)

Genmab A (GMAB) has reported Receivables - Other for 8 consecutive years, with $48.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables - Other changed N/A year-over-year to $48.0 million; the trailing twelve-month figure through Jun 2026 stood at $48.0 million (changed N/A YoY), and the FY2025 full-year result was $62.0 million, up 26.53% from the prior year.
• Receivables - Other slipped to $48.0 million in Q2 2026 per GMAB's latest filing, from $62.0 million in the prior quarter.
• Across five years, Receivables - Other topped out at $62.0 million in Q4 2025 and bottomed at $12.0 million in Q4 2022.
• Historically, Receivables - Other has averaged $43.2 million across 5 years, with a median of $48.0 million in 2026.
• The sharpest annual moves came in 2023 and 2024: Receivables - Other jumped 407.26% in 2023, then sank 46.21% in 2024.
• Over 5 years, Receivables - Other stood at $12.0 million in 2022, then surged by 407.26% to $61.1 million in 2023, then tumbled by 46.21% to $32.8 million in 2024, then surged by 88.77% to $62.0 million in 2025, then slipped by 22.58% to $48.0 million in 2026.
• According to Business Quant data, Receivables - Other over the past three periods registered $48.0 million, $62.0 million, and $32.8 million for Q2 2026, Q4 2025, and Q4 2024 respectively.